Javelin Signs $71 Million European Commercialization Partnership

Javelin Pharmaceuticals, Inc. announced that it has entered into an exclusive European marketing partnership for Dyloject (diclofenac sodium for injection) with Therabel Pharma N.V., worth up to $71 million in upfront, sales, and regulatory milestone payments plus a double digit royalty on future sales.
The Earth Times